Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis
Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.


GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > Reduvo NOT anytime soon , just more exaggeration !
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(58)
•••
Post by SamV21on Jun 08, 2022 11:47pm
265 Views
Post# 34742501

Reduvo NOT anytime soon , just more exaggeration !

Reduvo NOT anytime soon , just more exaggeration !  Dronabinol is number 16 in line now.SORT BY SUBMISSION DATE ,3rd row , there is a drug that was submitted FEB 2020 still has not been approved that is 2 years 4 months ago, Dronabinol is a narcotic my guess is 18 months min. which puts us into end of 2022 beginning of 2023 , IF AT ALL .Guy has no clue after hiring all these so called experts that have submitted drugs before as to timelines with Health Canada and yes he can check with Health Canada on where we are in line, we the shareholders should not have to check that site , that is his job and then report to the shareholders.
Oh just wait we don't need a CEO Golddetector knows it all , pumping warrants at .19 cents then .12 cents those warrants are .02 cents today , he seems to know exactly to the year when anything will happen , Guys right hand pumper ! Scammed us all. Any day now , any week now , next month will be big , 2020 the breakout year , Guy was going to be marketing Reduvo end of 2020 , he told us . The stock is being sold off right now see you at .05 soon.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities